D-Dimer: A Primer Biomarker in COVID-19

作者：Niraj Chawda, Suresh Jain, Bhagirath Solanki, Chetan Sonkar, Simran Arora, Sukruti Shah, Vtrag Tejani, Jyot Kaur Chawla, Mukesh Chaudhari, Ravi Chaudhari, Amal Bhattacharya · 发表于：Asian Journal of Medicine and Health · 年份：2023 · DOI：10.9734/ajmah/2023/v21i10883 · 被引用次数：2 · 研究领域：COVID-19 Clinical Research Studies、Dermatological and COVID-19 studies、Venous Thromboembolism Diagnosis and Management

Aim and Objective: To explore risk factors associated with mortality in COVID-19 patients and assess the use of D-dimer as a first line biomarker for disease severity and clinical outcome. Materials and Methods: We retrospectively analysed the pathological and radiological characteristics of 2087 consecutive cases of COVID-19 in PSH, Vadodara, Gujarat, from March 2021 to July 2022. Graphically, MS-Excel with median values were used. Correlations of D-dimer upon admission with disease severity and in-hospital mortality were analysed accordingly. Data were collected in MS-Excel with median values. Results: 2087 patients having positive RT-PCR and confirm diagnosis of Covid-19 were included upon hospital admission. Whereas, 65.78% (n= 1373) were male and 34.21% (n= 714) were female. Mean age was 52± 4 year. D-dimer level > 250 ng/mL at the time of hospital admission was the only fluctuating value accompanying with increased mortality [(95% CI), P = 0.025]. D-dimer elevation (≥250 ng/mL) was seen in 81.31% patients. Pericardial effusion and Deep vein thrombosis were ruled out in probability of thrombosis based on 2-D echo, X-ray chest and USG. This recommend that hyper-coagulopathy of the fibrin plays a significant role in the occurrence of thromboembolic complications with COVID-19 patients. D-dimer levels was crucially escalated with increasing severity of COVID-19 as determined by clinical improvement (within 5 days of hospital stay) and chest CT staging (CO-RADS score out ...